Tourette syndrome - Pipeline Review, H1 2019
DESCRIPTION
TABLE OF CONTENTS
RELATED REPORTS
SAMPLE REQUEST
REVIEWS
DESCRIPTION
Tourette syndrome - Pipeline Review, H1 2019
Summary
Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Tourette syndrome - Pipeline Review, H1 2019, provides an overview of the Tourette syndrome (Central Nervous System) pipeline landscape.
Tourette syndrome (TS) is a neurological disorder characterized by repetitive, stereotyped, involuntary movements and vocalizations called tics. Symptoms include eye blinking and other eye movements, facial grimacing, shoulder shrugging, and head or shoulder jerking. Other symptoms include touching the nose, smelling objects, flapping the arms and hopping. The predisposing factors include age. Males are about three to four times more likely than females to develop Tourette syndrome. Treatment includes antidepressants, stimulant medications and behavior therapy.
Report Highlights
Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Tourette syndrome - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Tourette syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Tourette syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Tourette syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Unknown stages are 2, 5, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Tourette syndrome (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Tourette syndrome (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Tourette syndrome (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Tourette syndrome (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Tourette syndrome (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Tourette syndrome (Central Nervous System)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Tourette syndrome (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Tourette syndrome (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Summary
Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Tourette syndrome - Pipeline Review, H1 2019, provides an overview of the Tourette syndrome (Central Nervous System) pipeline landscape.
Tourette syndrome (TS) is a neurological disorder characterized by repetitive, stereotyped, involuntary movements and vocalizations called tics. Symptoms include eye blinking and other eye movements, facial grimacing, shoulder shrugging, and head or shoulder jerking. Other symptoms include touching the nose, smelling objects, flapping the arms and hopping. The predisposing factors include age. Males are about three to four times more likely than females to develop Tourette syndrome. Treatment includes antidepressants, stimulant medications and behavior therapy.
Report Highlights
Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Tourette syndrome - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Tourette syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Tourette syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Tourette syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Unknown stages are 2, 5, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Tourette syndrome (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Tourette syndrome (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Tourette syndrome (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Tourette syndrome (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Tourette syndrome (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Tourette syndrome (Central Nervous System)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Tourette syndrome (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Tourette syndrome (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
TABLE OF CONTENTS
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Tourette syndrome - Overview
Tourette syndrome - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Tourette syndrome - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tourette syndrome - Companies Involved in Therapeutics Development
Abide Therapeutics Inc
Catalyst Pharmaceuticals Inc
KemPharm Inc
Neurocrine Biosciences Inc
SOM Biotech SL
Teva Pharmaceutical Industries Ltd
Therapix Biosciences Ltd
Tourette syndrome - Drug Profiles
(amfetamine + guanfacine) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ABX-1431 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bevantolol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CPP-115 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
deutetrabenazine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ecopipam hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize DRD2 for CNS Disorders and Hormonal Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
THX-110 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
THX-120 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
valbenazine tosylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tourette syndrome - Dormant Projects
Tourette syndrome - Discontinued Products
Tourette syndrome - Product Development Milestones
Featured News & Press Releases
Dec 13, 2018: Neurocrine reports negative top line results from T-Force GOLD study
Oct 18, 2018: Abide Therapeutics starts Phase II trial of Tourette syndrome drug
Jun 11, 2018: Therapix Biosciences Sponsors the 2018 Annual Meeting of the European Society for the Study of Tourette syndrome
Apr 10, 2018: Abide Therapeutics Presents Positive Data from a Phase 1b Study of ABX-1431 in Tourette syndrome at the American Academy of Neurology 70th Annual Meeting
Apr 09, 2018: Therapix Biosciences Announces Top line Results of Phase IIa Study at Yale University for Tourette syndrome Program
Feb 28, 2018: Nuvelution Pharma Announces Commencement of Patient Enrollment in Phase II/III Clinical Study of AUSTEDO (deutetrabenazine) for the Treatment of Tourette syndrome in Pediatric Patients
Feb 07, 2018: Abide Therapeutics to Participate in February 2018 Investor Conferences
Feb 07, 2018: Therapix Biosciences Completes Pre-IND Communication With FDA on THX-110 for Tourette syndrome: Clinical Development to Proceed as Projected
Dec 04, 2017: Therapix Biosciences Announces Completion of Enrollment of Phase IIa Study at Yale University for Tourette syndrome Program
Nov 28, 2017: Abide Therapeutics Reports Positive Topline Data from Phase 1b Study of ABX-1431 in Tourette syndrome
Oct 25, 2017: Neurocrine Initiates Phase IIb Clinical Study of Once-daily INGREZZA in Children and Adolescents with Tourette syndrome
Oct 23, 2017: Neurocrine Granted FDA Orphan Drug Designation for Valbenazine for the Treatment of Pediatric Patients With Tourette syndrome
Oct 11, 2017: Nippon Chemiphar and SOM Biotech to Cooperate on New, Orphan Disease Indications for Bevantolol (Calvan)
May 23, 2017: Neurocrine Announces Phase II Results of VMAT2 Inhibitor INGREZZA For Treatment of Tourette syndrome
May 08, 2017: Therapix Biosciences and the Hannover Medical School Enter into an Investigator-initiated Clinical Trial Agreement to Assess the Effect of TXH-TS01 in Patients with Tourette syndrome
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List Of Tables
Number of Products under Development for Tourette syndrome, H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products under Development by Universities/Institutes, H1 2019
Products under Development by Companies, H1 2019
Products under Development by Universities/Institutes, H1 2019
Number of Products by Stage and Target, H1 2019
Number of Products by Stage and Mechanism of Action, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Tourette syndrome - Pipeline by Abide Therapeutics Inc, H1 2019
Tourette syndrome - Pipeline by Catalyst Pharmaceuticals Inc, H1 2019
Tourette syndrome - Pipeline by KemPharm Inc, H1 2019
Tourette syndrome - Pipeline by Neurocrine Biosciences Inc, H1 2019
Tourette syndrome - Pipeline by SOM Biotech SL, H1 2019
Tourette syndrome - Pipeline by Teva Pharmaceutical Industries Ltd, H1 2019
Tourette syndrome - Pipeline by Therapix Biosciences Ltd, H1 2019
Tourette syndrome - Dormant Projects, H1 2019
Tourette syndrome - Discontinued Products, H1 2019
List Of Figures
Number of Products under Development for Tourette syndrome, H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products by Top 10 Targets, H1 2019
Number of Products by Stage and Top 10 Targets, H1 2019
Number of Products by Top 10 Mechanism of Actions, H1 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019
Number of Products by Stage and Routes of Administration, H1 2019
Number of Products by Stage and Molecule Types, H1 2019
RELATED REPORTS
Tourette Syndrome Disease - Global Clinical Trials Review, H2, 2020
Tourette Syndrome Disease - Global Clinical Trials Review, H2, 2020This clinical trial report, Tourette Syndrome Disease - Global Clinical Trials Review, H2, 2020 provides an overview of Tourette Syndrome Clinical
View ReportTourette Syndrome Global Clinical Trials Review, H1, 2020
Tourette Syndrome Global Clinical Trials Review, H1, 2020Its clinical trial report, Tourette Syndrome Global Clinical Trials Review, H1, 2020 provides an overview of Tourette Syndrome Clinical trials scenario. This report
View ReportMarfan Syndrome - Global Clinical Trials Review, H2, 2021
Marfan Syndrome - Global Clinical Trials Review, H2, 2021GlobalDatas clinical trial report, Marfan Syndrome - Global Clinical Trials Review, H2, 2021 provides an overview of Marfan Syndrome Clinical trials scenario.
View ReportCarcinoid Syndrome - Pipeline Insight, 2021
DelveInsights, Carcinoid Syndrome - Pipeline Insight, 2021, report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Carcinoid Syndrome pipeline landscape. It covers the pipeline drug profiles, including
View ReportSAMPLE REQUEST
Fill The Form For Sample Request
REVIEWS
